Bullish Case: FDA clearance and initiation of late stage clinical development of NTLA-2001, possibly the first in vivo CRISPR therapy [biospace.com, Yahoo], might invigorate investor optimism, stimulating a potential rise in NTLA's stock price.


Show historical bullish cases

Bearish Case: Poor past stock performance [Helium, Helium, Helium, Helium, Helium] combined with financial challenges, as evidenced by negative net margins and return on equity [defenseworld.net], suggests a possible negative course for the future of NTLA stock price.


Show historical bearish cases

Takeaway: Intellia’s future hinges on the successful execution and outcome of upcoming trials, particularly with NTLA-2001. Despite commendable scientific advancements, financial performance and past stock trends present a headwind [defenseworld.net, Helium].


Show historical takeaways

Potential Outcomes:

1. Advancement in clinical trials leads to definitive product approval (65%): Driven by the already obtained FDA clearance, the successful clinical trials of NTLA-2001 could place Intellia as a leader in novel in vivo CRISPR therapies [biospace.com, Yahoo]. Actualization depends on timely completion of trials and positive consequent outcomes.

2. Regulatory setbacks or failure in upcoming trials (35%): Unfavorable results from forthcoming trials of their key products, or unexpected regulatory roadblocks [Helium], could halt prospective growth in stock and lead to decline in price. Criticality underscored by earlier earnings shortfalls [defenseworld.net].


November 15, 2023


Correlated Stock Forecasts

Assets that tend to move strongly with NTLA



NNOX Forecast + Options Trading Strategies   [NNOX]  Nano X Imaging (0.78)


PRTA Forecast + Options Trading Strategies   [PRTA]  Prothena (0.78)


MTTR Forecast + Options Trading Strategies   [MTTR]  Matterport (0.74)


LMND Forecast + Options Trading Strategies   [LMND]  Lemonade (0.72)


EQR Forecast + Options Trading Strategies   [EQR]  Equity Residential Properties (0.72)



Uncorrelated Stock Forecasts

Assets with little price relationship to NTLA



CDAY Forecast + Options Trading Strategies   [CDAY]  Ceridian HCM (-0.0)


BDRY Forecast + Options Trading Strategies   [BDRY]  Breakwave Dry Bulk Shipping (0.0)


ROM Forecast + Options Trading Strategies   [ROM]  ProShares Ultra Technology (0.0)


BUG Forecast + Options Trading Strategies   [BUG]  Global X Cybersecurity (0.0)


VGT Forecast + Options Trading Strategies   [VGT]  Vanguard Information Technology (0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against NTLA



USL Forecast + Options Trading Strategies   [USL]  United States Commodity Funds LLC - United States 12 Month Oil (-0.56)


USO Forecast + Options Trading Strategies   [USO]  United States Commodity Funds (-0.56)


DLO Forecast + Options Trading Strategies   [DLO]  DLocal (-0.56)


X Forecast + Options Trading Strategies   [X]  United States Steel (-0.61)


BBW Forecast + Options Trading Strategies   [BBW]  Build A Bear Workshop (-0.63)